TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03263871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTM202
Description: PTM202 given twice daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micro-nutrient sprinkles
Description: Micro-nutrient sprinkles will be given twice daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-nutrient sprinkles
Description: Micro-nutrient sprinkles will be given twice daily for 30 days.
Study: NCT01631370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
Study: NCT01211626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule
Study: NCT02265237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets
Study: NCT03593668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benaglutide
Description: 2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH
Study: NCT04783753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole QD for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepin
Description: Subjects will receive carbamazepine BID for 23 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine BID for 8 days
Study: NCT03445468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Quadrivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine Pre-filled Syringe
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study: NCT02631798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food grade dye mucosal staining
Description: mucosal staining with food grade dye
Study: NCT01682837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
Study: NCT04912635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neo App
Description: Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
Study: NCT03402165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
Description: Response to DAAD's and developing HCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
Description: Response to DAAD's and developing HCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
Description: Response to DAAD's and developing HCC
Study: NCT04230954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG oral once a day
Description: Cabozantinib 40 mg oral once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks
Description: Pembrolizumab 200 mg IV every 3 weeks
Study: NCT01678924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 given as injections into the area of pain on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 given as injections into the area of pain on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 given as injections into the area of pain on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-214868 Placebo (Vehicle)
Description: AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
Study: NCT01682837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
Study: NCT01122043

Intervention type: DEVICE
Intervention: Endoglide
Description: Device
Study: NCT04117217

Intervention type: DIAGNOSTIC_TEST
Intervention: Labs drawn
Description: We will collect blood samples/biomarkers at the time of enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Labs drawn
Description: We will collect blood samples/biomarkers at the time of enrollment.
Study: NCT01946971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00303381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 44 microgram
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered subcutaneously, three times a week up to Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 66 microgram
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Study: NCT01682837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
Study: NCT04537585

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tomeka®
Description: Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
Study: NCT04537585

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tomeka®
Description: Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernonia amygdalina
Description: Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity).
Study: NCT04537585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernonia amygdalina
Description: Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity).
Study: NCT00569335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Irinotecan, Bevacizumab
Description: S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1.
Study: NCT04405674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
Study: NCT02135094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy device
Description: low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound therapy device
Description: The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
Study: NCT03720522

Intervention type: PROCEDURE
Intervention: Short cardiovascular MRI (CMR)
Description: A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).

Intervention type: PROCEDURE
Intervention: Short cardiovascular MRI (CMR)
Description: A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).

Intervention type: PROCEDURE
Intervention: Short cardiovascular MRI (CMR)
Description: A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).

Intervention type: PROCEDURE
Intervention: Short cardiovascular MRI (CMR)
Description: A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).

Intervention type: PROCEDURE
Intervention: Adenosine-perfusion cardiovascular MRI (CMR)
Description: An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Study: NCT03720522

Intervention type: PROCEDURE
Intervention: Adenosine-perfusion cardiovascular MRI (CMR)
Description: An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.

Intervention type: PROCEDURE
Intervention: Adenosine-perfusion cardiovascular MRI (CMR)
Description: An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.

Intervention type: PROCEDURE
Intervention: Urine (collection over 24h)
Description: The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months

Intervention type: PROCEDURE
Intervention: Urine (collection over 24h)
Description: The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months

Intervention type: PROCEDURE
Intervention: Urine (collection over 24h)
Description: The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months

Intervention type: PROCEDURE
Intervention: Urine (collection over 24h)
Description: The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months
Study: NCT02410031

Intervention type: DRUG
Intervention: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
Description: Cyproterone acetate 2mg/ethinylestradiol 35 μg
Study: NCT01674959

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks).
Study: NCT04075188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
Study: NCT04442373

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: 1.8 ml blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: 1.8 ml blood sample